Filing Summary
Filing and period: Form 8-K filed by Adagio Therapeutics, Inc. (now identified in the request metadata as Invivyd, Inc.), reporting events dated July 1 and July 5, 2022. The filing covers corporate governance and executive compensation matters, not periodic financial results.
Business Context and Reporting Period
The company was a Delaware biotechnology issuer headquartered in Waltham, Massachusetts, with common stock traded on Nasdaq under the symbol ADGI at the time of filing. The filing reports changes following the 2022 annual meeting of stockholders and the appointment of a permanent chief executive officer.
Key Financial and Operating Metrics
- The filing does not provide revenue, net income, margins, operating cash flow, cash balance, debt, liquidity, or other periodic financial metrics.
- David Hering’s annual base salary as chief executive officer is $600,000.
- His initial target annual cash bonus is 60% of base salary, subject to performance goals established by the Compensation Committee.
- The 2022 bonus will be calculated using a blended, prorated base-salary rate reflecting his service as chief operating officer, interim chief executive officer, and chief executive officer.
- The company granted Mr. Hering an option to purchase 2,000,000 common shares. The exercise price equals the Nasdaq closing price on July 5, 2022, but the filing text provided does not state that price.
- The option vests monthly over 48 months beginning on July 5, 2022.
- Mr. Hering may receive an additional option for up to 1,000,000 shares if specified performance goals are achieved by December 31, 2022. The filing does not identify the goals or quantify the probability of achievement.
Material Changes Versus the Prior Comparable Period
- Mr. Hering was appointed chief executive officer effective July 5, 2022, replacing his interim role. He had served as interim chief executive officer since February 2022 and chief operating officer since June 2021.
- He was also appointed a Class III director, with a term expiring at the 2024 annual meeting of stockholders.
- A new employment agreement superseded his prior employment agreement and amendments.
- The filing references board changes announced after the annual meeting, but the provided text does not specify the directors elected, removed, or otherwise affected.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- No financial guidance or operating outlook is provided.
- The employment agreement provides severance upon termination by the company without cause or by Mr. Hering for good reason, subject to a separation agreement and general release.
- Outside a change-in-control period, severance generally includes 12 months of base salary, the target bonus for the termination year, any earned bonus, outplacement services, and 12 months of continued benefits. Certain equity awards that would vest during the following 12 months would accelerate.
- During the defined change-in-control period, the severance cash and benefits are generally similar, while outstanding equity awards receive immediate acceleration and full vesting, subject to the agreement’s conditions.
- The employment agreement includes customary confidentiality, invention-assignment, noncompetition, and nonsolicitation provisions, as well as standard benefits and indemnification arrangements.
- The company disclosed no family relationships or related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Facts Investors Should Verify
- Confirm the company’s current legal name and ticker, because the filing identifies the registrant as Adagio Therapeutics, Inc., while the request identifies Invivyd, Inc.
- Review the complete July 5, 2022 employment agreement for the precise definitions of cause, good reason, change in control, and performance goals.
- Verify the exercise price and accounting treatment of the 2,000,000-share option grant.
- Determine whether the additional option for up to 1,000,000 shares was ultimately earned or granted.
- Review the July 1 annual-meeting press release for the specific board changes and voting results, which are not detailed in the supplied filing text.
- Consult subsequent periodic filings for the company’s actual financial condition, liquidity, clinical progress, and any effects of the executive transition.